🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Bayer ordered to pay $1.56 billion in latest US trial loss over Roundup weedkiller

Published 11/19/2023, 11:35 AM
Updated 11/20/2023, 11:58 AM
© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay
BAYRY
-

By Tom Hals

(Reuters) - A Missouri jury ordered Bayer (OTC:BAYRY) to pay $1.56 billion to four plaintiffs who claimed the company's Roundup weedkiller caused injuries including cancer, a verdict that could intensify investor pressure on the German drugs and agricultural chemicals company to change its legal strategy.

The Cole County, Missouri jury found on Friday that Bayer's Monsanto (NYSE:MON) business was liable for claims of negligence, design defects and failing to warn plaintiffs of the potential dangers of using Roundup, according to court documents.

Valorie Gunther of New York, Jimmy Draeger of Missouri and Daniel Anderson of California were awarded a combined $61.1 million in compensatory damages and $500 million each in punitive damages. Each was diagnosed with non-Hodgkin lymphoma that they alleged was caused by using Roundup on their family property. Draeger's wife Brenda was awarded $100,000 for the harm she allegedly suffered from her husband's disease.

The punitive damages could be reduced on appeal as it exceeds U.S. Supreme Court guidance.

Bayer has said that decades of studies have shown Roundup and its active ingredient, glyphosate, are safe for human use.

The verdict is the fourth straight loss in court for Bayer, after the company had been found not liable to plaintiffs in nine consecutive trials. Earlier this month, Union Investment, one of Bayer's top 10 shareholders, called on the company to consider trying to engage with plaintiffs to settle more cases.

Bart Rankin, partner at Forrest Weldon which represented the plaintiffs, said in a statement the victory was the first of many on behalf of thousands of plaintiffs.

Bayer said in a statement that it has strong arguments to get the recent verdicts overturned on appeal.

It said in the recent trials that have gone against the company, courts have improperly permitted plaintiffs to misrepresent the European Union's renewal process for glyphosate and the safety assessment by the U.S. Environmental Protection Agency.

The EU Commission said last week it would renew its approval of glyphosate based on safety assessments of the European Food Agency and European Chemicals Agency after EU member states failed to give a clear opinion on the renewal.

© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay

Around 165,000 claims have been made against the company for personal injuries allegedly caused by Roundup, which Bayer acquired as part of its $63 billion purchase of agrochemical company Monsanto in 2018.

In 2020, Bayer settled most of the then-pending Roundup cases for up to $10.9 billion. Around 50,000 claims remain pending, according to regulatory filings.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.